A pandemic doesn’t wait for us to be ready. That’s exactly why agreements like this one matter. Gonzalo Pereira, CSL Seqirus Building Vaccine Preparedness Through Long-Term Partnerships In FY26, CSL Seqirus strengthened influenza preparedness across the Middle East, Latin America and Canada, using long-term partnerships to build more reliable vaccine supply and the capacity to respond quickly when a pandemic occurs. In Saudi Arabia, CSL Seqirus partnered with the Ministry of Health and Vaccine Industrial Company to establish local manufacturing of cell-based seasonal and pandemic influenza vaccines, with the future facility expected to become the first of its kind in the Kingdom and the largest in the Middle East. “Through this collaboration… [we aim] to establish the Kingdom as a regional leader in preventing seasonal influenza,” said Dr. Lorna Meldrum, CSL Seqirus. In Latin America and the Caribbean, a new agreement with the Pan American Health Organization (PAHO) reserves millions of doses of pandemic influenza vaccine for participating countries, while CSL Seqirus and regional partner Sinergium Biotech will build local vaccine production and distribution capability. In Canada, a new agreement will provide adjuvanted cell-based influenza vaccines if a pandemic is declared, manufactured at CSL Seqirus’ new Tullamarine facility in Australia. Together, these partnerships combine secure vaccine supply with local and regional capabilities, helping countries be better prepared to protect their populations when the next influenza pandemic strikes. As Gonzalo Pereira of CSL Seqirus said: “A pandemic doesn’t wait for us to be ready. That’s exactly why agreements like this one matter.” CSL IMPACT REPORT 2026 | 29
RkJQdWJsaXNoZXIy MjE2NDg3